Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating…
Blog
PHBI – Phramagreen Targets Making Its Chibafreen Propriety Technology A Cannabis Industry Standard
Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), today released a second management update form CEO Peter Wojcik. Today’s…
DocNow – Reimagining Healthcare on the Digital Sphere
The ‘DocNow’ mobile app features an assortment of provisions that include instant access to user-specific Covid-19…
Aesthetic Lasers and Energy Devices Market to grow by USD 861.45mn|Evolving Opportunities with AbbVie Inc. & Bausch Health Companies Inc.| 17000+ Technavio Reports
The aesthetic lasers and energy devices market report offers information on several market vendors, including AbbVie Inc.,…
New HARMONY Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL) Research Results from HARMONY to facilitate tailored treatment choices in subtypes of blood cancer
Big Data analyses have produced novel insights that may improve the prognostication of patients with AML…
Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality…
AstraZeneca Levant recognized among the top workplaces in pharma for 2021
AstraZeneca Levant https://edenred.ae/, an affiliate of the multinational pharmaceutical and biotechnology company, has been recently recognized as one…
Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced initial positive results from a Phase 2/3 trial of intramuscular…
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today…
New Drug Combo May Improve Family-donated Stem Cells as Blood Cancer Treatment
A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient’s (host) body,…